AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03941093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Description: Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.
Study NCT03941093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
Description: Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil.
Study NCT04088994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOT Pathological Model Experimental Group
Description: The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
Study NCT04088994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AOT Healthy Model Control Group
Description: The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
Study NCT04569214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ320
Description: Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
Study NCT04569214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
Study NCT04569214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Treatment arm A - 4 tablets of placebo Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets
Study NCT01289392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: aerobic and resistance Physical exercise, three times a week, for four months
Study NCT01943864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (single tablet)
Description: The drug substance is blended with inert
Study NCT01943864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (Multiple tablet)
Description: The drug substance is blended with inert
Study NCT02572661 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation in Squamous Head and Neck Cancer
Study NCT03392519 — intervention group
Intervention type: OTHER
Intervention: Chronic stroke
Description: MRI data acquisition and behavioral test
Study NCT04209868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection
Description: As per arm description
Study NCT04209868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride 20mL Injection
Description: As per arm description
Study NCT03554499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bichectomy with hydrodissection
Description: Intraoral removal of buccal fat pads using hydrodissection technique
Study NCT03554499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bichectomy
Description: Intraoral removal of buccal fat pads using conventional technique
Study NCT05913557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behavior Therapy (RO DBT)
Description: Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
Study NCT02097706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NMDA receptor antagonist (active drug)
Study NCT02097706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose packed capsule (inert/inactive arm)
Study NCT03997539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
Study NCT03997539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of physician's choice
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
Study NCT03997539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: vinorelbine
Study NCT04330508 — intervention group
Intervention type: OTHER
Intervention: Depression and Cognitive Tests
Description: Health Related Quality of Life, neurocognitive tests, PHES
Study NCT02111824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIMIG System
Description: Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
Study NCT02111824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
Study NCT02389413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ912 oral
Study NCT02389413 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06691607 — intervention group
Intervention type: OTHER
Intervention: Serum NGAL level
Description: serum NGAL level
Study NCT04121273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:~Dose 1: 1x10\^7/m2~Dose 2: 3x10\^7/m2~Dose 3: 1x10\^8/m2~The cell numbers are calculated according to CAR-positive T cells.
Study NCT00783718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: Vedolizumab for intravenous infusion
Study NCT00783718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study NCT04462913 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention
Study NCT00547664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex recombinant , morphine, saline
Description: Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
Study NCT00547664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hylenex recombinant , morphine, saline
Description: Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
Study NCT00547664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
Study NCT01632865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenting
Description: Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
Study NCT02953548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT03033914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study NCT03033914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomycin: 10 units/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study NCT03033914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Vinblastine: 6 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Study NCT03033914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
Study NCT03033914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240mg q14 days
Study NCT02207530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 monotherapy
Study NCT02590016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Aspart
Description: Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
Study NCT02590016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Aspart
Description: Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
Study NCT02971644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cobalt alloy pedicle screw implantation
Description: The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
Study NCT04388735 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
Study NCT03556722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation.
Description: High frequency rTMS on left dorsolateral prefrontal cortex.
Study NCT03556722 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
Study NCT05537324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brazil nut
Description: Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts
Study NCT05537324 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coconut
Description: Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
Study NCT03105154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevena Dressing
Description: Prevena dressing is applied on one groin
Study NCT03105154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dressing
Description: Conventional dressing is applied on the contralateral groin
Study NCT01576861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatotropin
Description: Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
Study NCT02829086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relationship Enhancement
Description: Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
Study NCT02829086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Stress and Conflict Management
Description: Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
Study NCT02829086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Management
Description: Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
Study NCT00192335 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAIV-T
Study NCT00192335 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAIVT
Description: The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
Study NCT00192335 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
Study NCT05427851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
Study NCT01611506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1
Study NCT01611506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
Study NCT01611506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle
Study NCT04640194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
Study NCT03059030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Description: The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
Study NCT05427851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser - fonalaser
Description: diode laser beam application
Study NCT03313505 — intervention group
Intervention type: BIOLOGICAL
Intervention: S100B protein dosage
Description: S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
Study NCT03313505 — intervention group
Intervention type: OTHER
Intervention: Brain CT scan
Description: No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
Study NCT04640194 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
Study NCT02267512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-F
Description: Intravenous (IV)
Study NCT04640194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase low dose
Description: 0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
Study NCT04640194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase high dose
Description: 0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
Study NCT01777815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoChord DS1000 Artificial Chordae Delivery System
Study NCT00540358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: Gemcitabine and carboplatin administered according to instructions in the package inserts.
Study NCT00540358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin
Description: Gemcitabine and carboplatin administered according to instructions in the package inserts.
Study NCT00540358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iniparib
Description: Body weight adjusted dose~1 hour intravenous infusion
Study NCT02364869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharide
Description: Patients will be evaluated at baseline, week 6 and 12.
Study NCT02364869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
Study NCT04618172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minute long exercises twice a week
Study NCT01663896 — intervention group
Intervention type: DEVICE
Intervention: OCT stent guidance
Description: Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT
Study NCT03036592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
Study NCT03036592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late OGTT
Description: Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
Study NCT02604680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-1
Description: BLI1100-1 Topical gel
Study NCT02604680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-2
Description: BLI1100-2 Topical gel
Study NCT02604680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-3
Description: BLI1100-3 Topical gel
Study NCT02604680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI1100-4
Description: BLI1100-4 Topical gel
Study NCT02604680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Topical gel
Study NCT00385736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.